top of page

ANAVEX New Website - Untitled Page.png

Search

Dec 10, 2016

9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study

9th Clinical Trials on Alzheimer’s Disease (CTAD) 2016, San Diego, CA

Associate Professor Stephen Macfarlane, FRANZCP

View Presentation

Recent Posts

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

bottom of page